Table 2 Univariate and Multivariate analysis of progression free survival (PFS) and Overall survival (OS) among all tumors

 Incomplete resection

1.66

0.30–1.17

0.13

 WHO grade3

2.91

1.34–7.26

0.0057

 C11orf95-RELA fusion

0.59

0.29–1.50

0.29

 PFA

3.30

1.69–6.72

0.0004

 1q gain

3.21

1.50–6.48

0.0037

 EZH2 high expression

1.29

0.63–2.67

0.49

 TERT high expression

1.18

0.58–2.42

0.65

 TERT UTSS high methylation

1.42

0.72–2.96

0.32

 Local radiation therapy> = 50Gy

0.73

0.37–1.46

0.37

 Chemotherapy

1.48

0.74–2.90

0.26

 WHO grade3

1.33

0.53–3.66

0.55

 PFA

3.09

1.48–6.81

0.0024

 1q gain

2.79

1.25–5.99

0.014

 Incomplete resection

2.22

0.17–1.09

0.077

 WHO grade3

6.31

1.84–39.6

0.0017

 C11orf95-RELA fusion

0.46

0.07–1.61

0.25

 PFA

5.47

2.16–16.7

0.0002

 1q gain

1.57

0.51–3.99

0.40

 EZH2 high expression

1.21

0.46–3.21

0.70

 TERT high expression

0.76

0.29–1.94

0.57

 TERT UTSS high methylation

1.90

0.78–5.28

0.16

 Local radiation therapy> = 50Gy

1.22

0.48–3.31

0.68

 Chemotherapy

1.86

0.74–4.62

0.18

 WHO grade3

3.49

0.91–23.05

0.07

 PFA

3.54

1.33–11.4

0.01